About us | ST Diagnostic

ST INNOVATIVE DIAGNOSTICS

ST Innovative diagnostics’ team of renowned Hematology, Hemato-Oncology & Molecular Biology experts from Rabin Medical Center & Tel-Aviv University, Israel, collaborated to reach a significant breakthrough in non-invasive detection and monitoring of malignancies.

OUR MISSION

We aim to provide a multi-cancer early detection, screening & monitoring solution based on its proprietary simple, rapid & affordable blood test

OUR JOURNEY

For 14 years, Dr. Esther Rabizadeh (Ph.D.), our company founder & CSO, led pioneering research at Rabin Medical Center and Tel Aviv University, aimed at developing an innovative, simple, rapid & affordable blood test for multiple cancer type monitoring & early detection.

The resulting breakthrough technology, based on Fibrinogen Like Protein 2 (FGL2) activity in platelets, shows strong correlation with PET/CT imaging results and is protected by 7 patents across the US, Europe, China, Hong Kong, and Israel, owned by ST Innovative Diagnostics Ltd.

Our rigorous clinical validation included 3 years of clinical studies with 125 Aggressive Non-Hodgkin Lymphoma patients, along with successful proof-of-concept trials in Colon Cancer, Prostate Cancer, and Cutaneous T-Cell Lymphoma.

Currently, the company is heading toward multi-site clinical trials for early detection of NHL Primary refractory patients, monitoring treatment response and early relapse detection in metastatic Colorectal Cancer, and Pancreatic Cancer patients across Israel's top 8 medical centers.

We further aim to construct a comprehensive FGL2 baseline profiling database, utilizing AI-derived profile correlations to develop a predictive model and position FGL2 as a routine screening test for early cancer detection.

LEADERSHIP

DR. ESTHER RABIZADEH, PHD

Founder & CSO

Dr. Esther Rabizadeh is a highly accomplished expert in the fields of hemato-oncology and cell biology. With a distinguished career spanning decades, she served as the Managing Director of Hematology Laboratories at Rabin Medical Center and headed the Hemato-Oncology research team at the Felsenstein Medical Research Center (FMRC), Tel-Aviv University.

Dr. Rabizadeh's research contributions have been published in prestigious journals, including the Journal of Cancer Research Clinical Oncology, Cancer Research, Clinical Research, Experiment Oncology, and PLOS One, solidifying her reputation as an influential figure in her field.

Her recent focus the activity of Fibrinogen Like Protein 2 (FGL2) in malignancies, culminated in the creation of a revolutionary non-invasive predictive blood biomarker. This biomarker proficiently tracks malignancies and exhibits a robust correlation with PET/CT imaging.

Dr. Rabizadeh's remarkable work has led to impactful publications and the acquisition of patents in the United States, Europe, China, HK and Israel, demonstrating her significant contributions to cancer research and patient care.

SHEILA ALTMAN, LLB, MBA

CEO

A seasoned business manager and strategist, with a track record of growing businesses & products, through a unique blend of technological, business, and legal proficiencies within C-Level roles.

Sheila has over 15 years of experience in multinational corporates as well as startups, leading product, business & corporate growth strategies.

Sheila holds a Law degree from Tel-Aviv University, complemented by a MBA from Reichman University and is a member of the Israeli Bar since 2000.

BUSINESS AND ADVISORY TEAM

DANA COHEN, MSC

Advisory board

Possessing extensive expertise within both the private and public biotech sectors, Dana Cohen serves as a seasoned senior manager.

Additionally, Dana fulfills roles as an advisor to biotech organizations in Israel and the USA, while also providing business mentorship to institutions such as Tel Aviv and Bar Ilan Universities, as well as incubators and venture capitalists.

With a background in securing capital and a wealth of experience in navigating local and EU governmental funding opportunities, Dana Cohen brings a multifaceted perspective to her endeavors.

Dr. NIR SHTAYER , DVM

Advisory board

Leveraging over 20 years of global experience in both the pharmaceutical/Biotech industry and higher education sector, incl. MNCs (Omrix J&J, TEVA), Start-ups (PolyPid, Bonus BioGroup, CaVnox) and a Biotechnology Research Center of Excellence (UTS, Australia).

Former Head of Regulatory Affairs and Clinical Departments (Bio-pharmaceutical/Medical Device), including in Teva Pharmaceuticals.

Graduated as a Veterinar, D.V.M (the Koret, Veterinary School, University of Jerusalem, Israel) and holds an Executive MBA (from UTS, Australia).

SCIENTIFIC & MEDICAL ADVISORY

DR. IZHACK CHERNY, PHD

Scientific Advisor

Dr. Izhack Cherny is a seasoned investigator in the domains of biochemistry and hematology, boasting a doctoral degree from Tel Aviv University's Biotechnology department, alongside post-doctoral education accomplished at Princeton University's Chemistry Department in New Jersey.

With extensive proficiency in proteinaceous systems within the realm of biology, Dr. Cherny possesses a wealth of expertise encompassing protein functionality, structure, enzymology, interactions, engineering, the screening and formulation of inhibitors as well as cancer biology.

JUDITH CHEZAR, PHD

Scientific Editor

Former Director of Galilee Medical Center's Hematology Institute’s Laboratories. Oversaw a comprehensive range of labs encompassing General Hematology, Coagulation, Blood Bank, Flow Cytometry, and Molecular Biology dedicated to Hematological disorders.

Contributed expertise as a member of the Advisory Committee to the Ministry of Health, specializing in Transfusion Medicine.

Played a pivotal role as a co-organizer of the Flow Cytometry Forum within the Israel Society for Clinical Laboratory Sciences (ISCLS).

NURIT ROSENBERG, PHD

Medical Advisor

Accomplished professional with a robust background in Hematology.

Currently serving as a Senior Lecturer at the Sackler Faculty of Medicine, Tel-Aviv University, Israel.

A seasoned researcher with a notable tenure (1993-2021) at the Amalia Biron Research Institute of Thrombosis and Hemostasis, Tel-Aviv University.

Former head of the Coagulation Laboratory at both the Hemophilia National Center and Sheba Medical Center, Tel-Hashomer, from 2014 to 2020.

Currently serving as a Coagulation Counselor in the Blood Bank at Sheba Medical Center, Tel-Hashomer, offering expert insights in the realm of coagulation.

SUPPORTED BY:

KEY OPINION LEADERS & ESTEEMED CLINICIANS

CLINICIANS

Rabin Medical Center, Petah Tikva

Prof. Anat Gafter-Gvili, MD

Prof. Ronit Gurion, MD

Sheeba Medical Center (Tel-Hashomer)

Dr, Abraham Avigdor, MD

Soraski - Ichilov, Tel-Aviv

Prof. Irit Avivi, MD

Rambam Medical Center, Haifa

Dr. Shimrit Ringelstein Harlev , MD

Shaarei tzedek Medical Center, Jerusalem

Prof. Yishai Ophran, MD

Meir Medical Center, Kfar Saba

Dr. Gilad Itzhaki, MD

Wolfson Medical Center, Holon

Prof. Ronen Brenner, MD

Soroka Medical Center, Beer Sheva

Dr. Itai Levi

Key Opinion Leaders (KOLs )

Prof. Jonathan Friedberg, M.D Prof. Jakobe Rowe, M.D

Prof. Nir Peled, MD